Project Grant R21AI188089
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $444K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $195,819 to Duke University to conduct research on inducing xenotolerance via a chimeric thymus. The research aims to determine the ability of cultured postnatal pig thymus slices to attract human thymocyte precursors and antigen presenting cells, and support positive and negative selection in vivo in humanized...
- This federal Project Grant award of $1,031,754.00, awarded on September 2, 2025 by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research), supports research at The Johns Hopkins University to develop clinically relevant pharmacologic and immunomodulatory strategies to achieve long-term survival of kidney xenografts in primates. The research aims to advance understanding and treatment of infectious diseases and immune system disorders,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,273,991 Cooperative Agreement to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The funding supports research to investigate the physiology and early immune responses to genetically modified porcine liver xenografts using a human brain-dead donor...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,426,920 Cooperative Agreement under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct preclinical research on xenotransplantation of kidney, heart, and lung organs. The award aims to demonstrate consistent long-term, life-supporting xenograft survival in a nonhuman primate model,...
- This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $2,856,183 in funding to New York University School of Medicine to develop sensitive assays to detect host- and donor-derived microbes post-xenotransplantation, as well as assays to detect donor-derived cell-free DNA in recipient blood. The award period is from July 1, 2025 to May 31, 2030. This...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,937,578 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of North Carolina at Chapel Hill. The grant, awarded on August 18, 2025, supports the development of an ACE2 immunodecoy therapy for long-lasting immunoprophylaxis against SARS-CoV-2 variants and other zoonotic coronaviruses that target the human ACE2 receptor. The project aims to optimize the linkage...
- This federal Project Grant award, valued at $459,439.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research aimed at improving the understanding of alloreactivity, the immune response that leads to acute cellular rejection of transplanted tissues. The research seeks to identify the specific peptide-HLA complexes recognized by alloreactive T cells, which could...
- This Project Grant award of $3,192,404 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research on immunomodulation in adeno-associated virus (AAV) gene therapy. The research aims to better understand, model, and manage immune responses that can arise from systemic dosing of recombinant AAV vectors, which pose a major challenge in the treatment of monogenic disorders using this gene...
- This Project Grant award of $225,953 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Program (CFDA 93.855), supports research to define and characterize human B cells that are reactive to foreign glycans, or xenoglycans. The research aims to determine if xenoglycan-reactive B cells exist as a distinct subset compared to protein-reactive B cells, and to examine the molecular and functional features of these...
- This Project Grant award of $402,500 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to evaluate the use of anti-CD154 monoclonal antibody therapy in a nonhuman primate vascularized composite allograft (VCA) model. The research aims to determine the efficacy of this approach in regulating the host immune response and promoting transplantation tolerance, particularly in sensitized...